Biommune Technologie (BIMUF) 0.4267 $BIMUF
BioMmune Appoints Dr. Patrick Gray as New Chief Executive Officer and President
Marketwired - Fri Apr 22, 7:45AM CDT
BioMmune Technologies Inc. ("BioMmune" or the "Company"
(TSX VENTURE: IMU), a company focused on harnessing the body's immune system to fight cancer and autoimmune diseases, announces that Dr. Patrick W. Gray has been appointed to serve as Chief Executive Officer and President. Dr. Gray has worked in the biotechnology industry for the past 35 years with extensive experience in drug discovery at Genentech, ICOS, and Macrogenics. He also has previous executive experience as Chief Scientific Officer, CEO, and as member of Boards of Director. His previous drug discovery efforts led to the development of the Hepatitis B vaccine and multiple drugs (such as Interferon-gamma) and drug targets (CCR5 and PI3 Kinase p110delta). Former BioMmune CEO and President, Dr. Reinhard Gabathuler has resigned his positions to become Senior Vice-President of Business Development. In his new role, Dr. Gray will lead the company's R&D programs and financing activities, whereas Dr. Gabathuler will lead the company's partnering and business development activities. BioMmune anticipates increasing partnering efforts resulting from its progress in its oncology and immunology programs.
IMU.VN: 0.600 (+0.040)
bioMmune Technologies Inc. Announces Appointment of Directors
Marketwired - Tue Dec 08, 11:32PM CST
bioMmune Technologies Inc. ("bioMmune" or the "Company" (TSX VENTURE: IMU), a company focused on harnessing the body's immune system to fight cancer and autoimmune diseases, is pleased to announce that Patrick W. Gray, PhD and Reinhard Gabathuler, PhD have been elected as directors of the Company at its Annual and Special Meeting held on December 8, 2015 in Vancouver, B.C.
IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc.: Appointment of Chief Scientific Officer
Marketwired - Thu Nov 19, 8:31AM CST
BioMmune Technologies Inc. ("Biommune" or the "Company" (TSX VENTURE: IMU), a company focused on harnessing the body's immune system to fight cancer and autoimmune diseases, is pleased to announce that it has appointed Patrick W. Gray, Ph.D. as Chief Scientific Officer, effective December 2, 2015.
IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc. Announces Non-Brokered Private Placement
Marketwired - Sun Oct 11, 4:41PM CDT
BioMmune Technologies Inc. (the "Company" (TSX VENTURE: IMU), announces a non-brokered private placement of up to 2,000,000 units (each a "Unit" at a price of $0.30 per Unit for gross proceeds of up to $600,000. Each Unit will consist of one common share and one common share purchase warrant (each a "Warrant". Each Warrant entitles the holder to purchase one additional common share of the Company at a price of $0.40 per share for a period of 24 months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $0.60 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release.
IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc. Grants Stock Options
Marketwired - Tue Aug 04, 2:07PM CDT
BioMmune Technologies Inc. (TSX VENTURE: IMU) (the "Company" is pleased to announce that pursuant to the Company's Incentive Stock Option Plan (the "Plan", it has granted incentive stock options to directors and officers of the Company to purchase an aggregate of 750,000 common shares in the capital stock of the Company. The options are exercisable at a price of $0.31 per share (being the closing price of the Company's stock on Friday, July 31, 2015) for a period of five years from the date of grant.
IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc. Announces the Appointment of a New Director
Marketwired - Tue Jun 30, 3:06PM CDT
BioMmune Technologies Inc., (TSX VENTURE: IMU) (the "Company" is pleased to announce the appointment of Mr. Jens Biertumpel as a director of the Company.
IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc. Closes Non-Brokered Private Placement
Marketwired - Mon Jun 08, 5:01PM CDT
BioMmune Technologies Inc. (TSX VENTURE: IMU) (the "Company" is pleased to announce that it has closed its non-brokered private placement announced on May 3rd, 2015. The Company has issued 5,000,000 units (each a "Unit" at a price of CDN$0.20 per unit, for gross proceeds of CDN$1,000,000. Each Unit consists of one common share and one full common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CDN$0.30 per share for a period of eighteen months up to and including December 8th, 2016,, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $0.50 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. A cash finder's fees of CDN$70,400 was paid on a portion of the financing. All securities issued are subject to a hold period of four (4) months and one day and as such may not be traded until October 9th, 2015. The net proceeds from the sale of units have been added to working capital in furtherance of the Company's business.
IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc. Announces the Appointment of Expert in Biologics as New Director
Marketwired - Tue Dec 16, 8:30AM CST
BioMmune Technologies Inc., (TSX VENTURE: IMU) a company focused on harnessing the body's own immune system to fight cancer and autoimmune diseases, today welcomes Professor Terry Pearson to the Board of Directors of BioMmune Technologies Inc.
IMU.VN: 0.600 (+0.040)
BioMmune Appoints Dr. Patrick Gray as New Chief Executive Officer and President
Marketwired - Fri Apr 22, 7:45AM CDT
BioMmune Technologies Inc. ("BioMmune" or the "Company"
(TSX VENTURE: IMU), a company focused on harnessing the body's immune system to fight cancer and autoimmune diseases, announces that Dr. Patrick W. Gray has been appointed to serve as Chief Executive Officer and President. Dr. Gray has worked in the biotechnology industry for the past 35 years with extensive experience in drug discovery at Genentech, ICOS, and Macrogenics. He also has previous executive experience as Chief Scientific Officer, CEO, and as member of Boards of Director. His previous drug discovery efforts led to the development of the Hepatitis B vaccine and multiple drugs (such as Interferon-gamma) and drug targets (CCR5 and PI3 Kinase p110delta). Former BioMmune CEO and President, Dr. Reinhard Gabathuler has resigned his positions to become Senior Vice-President of Business Development. In his new role, Dr. Gray will lead the company's R&D programs and financing activities, whereas Dr. Gabathuler will lead the company's partnering and business development activities. BioMmune anticipates increasing partnering efforts resulting from its progress in its oncology and immunology programs. IMU.VN: 0.600 (+0.040)
bioMmune Technologies Inc. Announces Appointment of Directors
Marketwired - Tue Dec 08, 11:32PM CST
bioMmune Technologies Inc. ("bioMmune" or the "Company"
(TSX VENTURE: IMU), a company focused on harnessing the body's immune system to fight cancer and autoimmune diseases, is pleased to announce that Patrick W. Gray, PhD and Reinhard Gabathuler, PhD have been elected as directors of the Company at its Annual and Special Meeting held on December 8, 2015 in Vancouver, B.C. IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc.: Appointment of Chief Scientific Officer
Marketwired - Thu Nov 19, 8:31AM CST
BioMmune Technologies Inc. ("Biommune" or the "Company"
(TSX VENTURE: IMU), a company focused on harnessing the body's immune system to fight cancer and autoimmune diseases, is pleased to announce that it has appointed Patrick W. Gray, Ph.D. as Chief Scientific Officer, effective December 2, 2015. IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc. Announces Non-Brokered Private Placement
Marketwired - Sun Oct 11, 4:41PM CDT
BioMmune Technologies Inc. (the "Company"
(TSX VENTURE: IMU), announces a non-brokered private placement of up to 2,000,000 units (each a "Unit" at a price of $0.30 per Unit for gross proceeds of up to $600,000. Each Unit will consist of one common share and one common share purchase warrant (each a "Warrant". Each Warrant entitles the holder to purchase one additional common share of the Company at a price of $0.40 per share for a period of 24 months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $0.60 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc. Grants Stock Options
Marketwired - Tue Aug 04, 2:07PM CDT
BioMmune Technologies Inc. (TSX VENTURE: IMU) (the "Company"
is pleased to announce that pursuant to the Company's Incentive Stock Option Plan (the "Plan", it has granted incentive stock options to directors and officers of the Company to purchase an aggregate of 750,000 common shares in the capital stock of the Company. The options are exercisable at a price of $0.31 per share (being the closing price of the Company's stock on Friday, July 31, 2015) for a period of five years from the date of grant. IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc. Announces the Appointment of a New Director
Marketwired - Tue Jun 30, 3:06PM CDT
BioMmune Technologies Inc., (TSX VENTURE: IMU) (the "Company"
is pleased to announce the appointment of Mr. Jens Biertumpel as a director of the Company. IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc. Closes Non-Brokered Private Placement
Marketwired - Mon Jun 08, 5:01PM CDT
BioMmune Technologies Inc. (TSX VENTURE: IMU) (the "Company"
is pleased to announce that it has closed its non-brokered private placement announced on May 3rd, 2015. The Company has issued 5,000,000 units (each a "Unit" at a price of CDN$0.20 per unit, for gross proceeds of CDN$1,000,000. Each Unit consists of one common share and one full common share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the Company at a price of CDN$0.30 per share for a period of eighteen months up to and including December 8th, 2016,, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company's shares are trading at or above a volume weighted average price of $0.50 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release. A cash finder's fees of CDN$70,400 was paid on a portion of the financing. All securities issued are subject to a hold period of four (4) months and one day and as such may not be traded until October 9th, 2015. The net proceeds from the sale of units have been added to working capital in furtherance of the Company's business. IMU.VN: 0.600 (+0.040)
BioMmune Technologies Inc. Announces the Appointment of Expert in Biologics as New Director
Marketwired - Tue Dec 16, 8:30AM CST
BioMmune Technologies Inc., (TSX VENTURE: IMU) a company focused on harnessing the body's own immune system to fight cancer and autoimmune diseases, today welcomes Professor Terry Pearson to the Board of Directors of BioMmune Technologies Inc.
IMU.VN: 0.600 (+0.040)
